Ten years after the formation of biosimilar-focused joint venture Samsung Bioepis, Biogen is finally launching its first U.S. biosimilar. Together with Samsung Bioepis, Biogen is commencing marketing ...

A recent report from Korea buzzed a Biogen takeover by Samsung. Turns out, Samsung is indeed buying something of Biogen’s, just not the entire company that’s saddled with the Alzheimer’s disease drug ...

As previously reported, litigation between Johnson & Johnson and Janssen (“J&J”) and Samsung Bioepis (“Samsung”) involving Samsung’s ...

INCHEON, Korea, April 17, 2026--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE ®1), a biosimilar to Prolia 2 (denosumab) across ...

INCHEON, KOREA--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced its expansion into the Brazilian biopharmaceutical market. The first product available in the country is BRENZYS™ (etanercept ...

Please provide your email address to receive an email when new articles are posted on . Samsung Bioepis can launch Opuviz in the U.S. in January 2027. Opuviz, a biosimilar to Eylea, received FDA ...

Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to ...

This agreement enables Samsung Bioepis to launch Opuviz 2 mg in the United States starting in January 2027. Choi MacDonald continued, "We are well-positioned to successfully launch our aflibercept ...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that its rapidly growing biosimilar business will expand into mainland China through a licensing agreement with 3SBio Inc.

Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...

CAMBRIDGE, Mass. and INCHEON, Korea, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis today announced that they will present new real-world data from the companies’ ...

On June 2, 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing Genentech’s LUCENTIS®, will be available in the United States on July 1, ...